Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

• Andrew H. Wei,
• Panayiotis Panayiotidis,
• Pau Montesinos,
• Kamel Laribi,
• Vladimir Ivanov,
• Inho Kim,
• Jan Novak,
• Don A. Stevens,
• Walter Fiedler,
• Maria Pagoni,
• Julie Bergeron,
• Stephen B. Ting,
• Jing-Zhou Hou,
• Achilles Anagnostopoulos,
• Andrew McDonald,
• Vidhya Murthy,
• Takahiro Yamauchi,
• Jianxiang Wang,
• Brenda Chyla,
• Yan Sun,
• Qi Jiang,
• Wellington Mendes,
• John Hayslip,
• Courtney D. DiNardo

Affiliations

Andrew H. Wei

The Alfred Hospital and Monash University

Panayiotis Panayiotidis

National and Kapodistrian University of Athens Medical School, Laiko General Hospital

Pau Montesinos

Hospital Universitario y Politécnico La Fe

Kamel Laribi

Centre Hospitalier–Le Mans

Vladimir Ivanov

Almazov National Medical Research Center

Inho Kim

Seoul National University Hospital

Jan Novak

University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University

Don A. Stevens

Norton Cancer Institute

Walter Fiedler

Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf

Maria Pagoni

Evaggelismos General Hospital

Julie Bergeron

CIUSSS-EMTL, Installation Maisonneuve-Rosemont

Stephen B. Ting

Eastern Health and Monash University

Jing-Zhou Hou

University of Pittsburgh Medical Center (UPMC) Cancer Center

Achilles Anagnostopoulos

George Papanicolaou General Hospital

Andrew McDonald

Netcare Pretoria East Hospital

Vidhya Murthy

Heartlands Hospital

Takahiro Yamauchi

University of Fukui Hospital

Jianxiang Wang

Chinese Academy of Medical Sciences

Brenda Chyla

AbbVie Inc

Yan Sun

AbbVie Inc

Qi Jiang

AbbVie Inc

Wellington Mendes

AbbVie Inc

John Hayslip

AbbVie Inc

Courtney D. DiNardo

The University of Texas MD Anderson Cancer Center